The at-home isolation and social distancing orders for millions of Americans is a vital element to slow to the COVID-19 pandemic. With most of our daily activities on-hold or modified for the foreseeable future, medical research is a crucial pursuit that continues despite the current environment.
Considerations for Feasibility for Translational Research
For many researchers, considering the feasibility of a translational study with Sanguine Biosciences is a crucial yet challenging step. The proposed study they submit might not be possible based on real-world evidence or Sanguine’s service offerings, requiring them to modify their criteria.
The global search for a treatment targeting the novel coronavirus has led to an unlikely potential savior: a cocoa-colored llama named Winter, whose blood could hold a weapon to blunt the virus.
She lives at a research farm in Belgium with about 130 other llamas and alpacas.
Transcript
John:
We would like to welcome you to the Sanguine Speaker Series webinar, The Journey From Patient to Advocate to Leader: Changing the Clinical Research Game, presented by Rob Long. Rob is the executive director of Uplifting Athletes. I will now hand it over to Rob.
Systemic lupus erythematosus (SLE), also known as lupus, is a chronic autoimmune disease caused by random or inherited mutations in various genes of the immune system. It affects the skin, joints, kidneys, brain, and almost every other organ. People suffering from SLE experience inflammation in the connective tissues that provide strength and flexibility to structures throughout the body.
WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection.
Transcript:
Headline News:
Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30.
Liam Martin:
Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.
One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.
COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine.
In this Sanguine Speaker Series (3) virtual fireside chat, we will discuss:
Response efforts to the current COVID-19 pandemic
How does the race for the cure affect the hundreds of other drugs in development
COVID-19’s potential impact on the global pharmaceutical market?
A Novel Non-Covalent Modulator of Hemoglobin Improves Anemia and Reduces Sickling in a Mouse Model of Sickle Cell Disease.
Speaker: Kelly M. Knee, PhD, Senior Principal Scientist, Rare Disease Researcher Unit, Pfizer
Sickle cell disease is a severe genetic disorder caused by a single point mutation on the β-chain of adult hemoglobin (Hb A), β6 Glu→Val (Hb S).
COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine.
Moderator Craig Lipset – Independent Advisor, Former Head of Clinical Innovation, Pfizer
Transcript
John:
We would like to welcome you to the Sanguine Speaker Series Webinar on COVID-19; Navigating the Pandemic.
